Skip to content

US · AGEN · BIOTECHNOLOGY

Agenus Inc. (AGEN) intrinsic value and stock valuation

$5.97as of 2026-11-21 · Mkt cap 289.83M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Agenus Inc. DCF and intrinsic value

InvestorsCraft values AGEN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AGEN’s statements →

Agenus Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Lexington, MA 02421-7305 agenusbio.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$114.2M+5.3% 5y CAGRd
20112025
Net income
$120K
20112025
Free cash flow
-$-158.89M
20112025
Total equity
-$-277.86M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$114.2M$103.5M$156.3M$98M$295.7M
Operating income-$-20.56M-$-120.47M-$-159.55M-$-179.43M$25.8M
Net income$120K-$-227.21M-$-245.76M-$-220.07M-$-23.93M
EPSd$4.04K-$-10.58M-$-13.74M-$-15.62M-$-2.09M
Operating cash flow-$-158.31M-$-158.31M-$-224.2M-$-175.37M$10.1M
Capital expenditure-$-580K-$-580K-$-9.95M-$-53.06M-$-33.81M
Free cash flow-$-158.89M-$-158.89M-$-234.16M-$-228.44M-$-23.67M
Total assets$226.8M$226.3M$313.9M$413.6M$466M
Total debt$334.9M$94.9M$93.2M$78.4M$58.3M
Net debt$331.9M$54.4M$17.1M-$-100.25M-$-233.64M
Total equity-$-277.86M-$-306.42M-$-148.38M-$-54.9M$47.9M
Cash and short-term investments$3M$40.4M$76.1M$193.4M$306.9M
Income statement
20252024202320222021
Revenue$114.2M$103.5M$156.3M$98M$295.7M
Cost of revenue$80.4M$156M$237.7M$197.3M$182.1M
Gross profit$33.8M-$-52.55M-$-81.37M-$-99.23M$113.6M
Research and development expenses$0.00$155.5M$234.6M$0.00$178.6M
Selling, general and administrative expenses$54.4M$71.9M$78.7M$81M$76.4M
Other expenses$0.00-$-159.48M-$-235.12M-$-810K-$-167.13M
Operating expenses$54.4M$67.9M$78.2M$80.2M$87.8M
Cost and expenses$134.8M$223.9M$315.9M$277.5M$269.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$55.3M$117.6M$97.9M$61.9M$65.7M
Depreciation and amortization$10M$13.3M$13.6M$6.95M$6.79M
Ebitda$62.2M-$-101.3M-$-145.92M-$-161.85M$43.8M
Operating income-$-20.56M-$-120.47M-$-159.55M-$-179.43M$25.8M
Total other income/expenses, net$17.5M-$-111.8M-$-97.89M-$-51.23M-$-54.47M
Income before tax-$-3.08M-$-232.27M-$-257.44M-$-230.66M-$-28.72M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$120K-$-227.21M-$-245.76M-$-220.07M-$-23.93M
Weighted average shares outstanding$29.7M$21.5M$17.9M$14.1M$11.5M
Weighted average diluted shares outstanding$29.7M$21.5M$17.9M$14.1M$11.5M
Balance sheet
20252024202320222021
Cash and short-term investments$3M$40.4M$76.1M$193.4M$306.9M
Net receivables$1.83M$410K$25.8M$2.74M$1.52M
Inventory$0.00$0.00$0.00$13.8M$20.4M
Total current assets$133.4M$45.6M$112.4M$213.1M$332M
Property, plant and equipment, net$24.3M$147.4M$163M$164.3M$91.1M
Goodwill and intangible assets$27.1M$27.5M$29.1M$31.7M$33.4M
Long-term investments$42.7M$4.64M$3.22M$0.00$0.00
Total non-current assets$93.4M$180.7M$201.5M$200.4M$134M
Total assets$226.8M$226.3M$313.9M$413.6M$466M
Accounts payable$83M$61.5M$61.5M$40.9M$30.5M
Short-term debt$156.3M$9.85M$13.2M$2.52M$3.35M
Deferred revenue$1.14M$30K$20K$12.3M$12.4M
Total current liabilities$323.5M$221.4M$255.9M$189M$156.9M
Long-term debt$179.8M$85M$80M$75.9M$54.9M
Deferred revenue, non-current$1.14M$1.14M$1.14M$1.14M$11.2M
Total non-current liabilities$181.2M$311.3M$206.4M$279.5M$261.1M
Capital lease obligations$11.3M$61.7M$80.3M$65.3M$44.7M
Total liabilities$504.7M$532.7M$462.3M$468.5M$418.1M
Common stock$350K$240K$3.94M$3.06M$2.57M
Retained earnings-$-2.18B-$-2.18B-$-1.96B-$-1.71B-$-1.49B
Accumulated other comprehensive income (loss)-$-440K-$-1.4M-$-950K$920K$1.49M
Total equity-$-277.86M-$-306.42M-$-148.38M-$-54.9M$47.9M
Total investments$42.7M$4.64M$3.22M$14.7M$15M
Total debt$334.9M$94.9M$93.2M$78.4M$58.3M
Net debt$331.9M$54.4M$17.1M-$-100.25M-$-233.64M
Cash flow statement
20252024202320222021
Net income-$-232.27M-$-232.27M-$-257.44M-$-230.66M-$-28.72M
Depreciation and amortization$13.3M$13.3M$13.6M$6.95M$6.79M
Stock-based compensation$17.4M$17.4M$22.9M$18.3M$19.6M
Change in working capital$27.3M$32.6M$10.8M$24.1M-$-9.74M
Accounts receivable-$-1.73M$25.3M-$-23.46M$120K-$-390K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$23.5M$2.01M$21.4M$6.49M$10.8M
Net cash provided by operating activities-$-158.31M-$-158.31M-$-224.2M-$-175.37M$10.1M
Investments in property, plant and equipment-$-580K-$-580K-$-9.95M-$-53.06M-$-33.81M
Acquisitions, net$0.00$0.00$0.00-$-2.92M$0.00
Net cash used for investing activities$30K$30K$3.4M-$-33.61M-$-43.15M
Common stock issued$36.3M$38.8M$133.2M$99.2M$220.7M
Common stock repurchased-$-90K$0.00-$-5.17M-$-3.79M-$-1.65M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$122.8M$122.8M$119.9M$95.8M$225.3M
Net change in cash-$-35.71M-$-35.71M-$-101.56M-$-113.26M$192.1M
Cash at end of period$44.1M$44.1M$79.8M$181.3M$294.6M
Operating cash flow-$-158.31M-$-158.31M-$-224.2M-$-175.37M$10.1M
Capital expenditure-$-580K-$-580K-$-9.95M-$-53.06M-$-33.81M
Free cash flow-$-158.89M-$-158.89M-$-234.16M-$-228.44M-$-23.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Agenus Inc.

        Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

        CEO
        Garo H. Armen
        Employees
        81
        Beta
        1.55

        Explore

        Frequently asked questions

        What is the intrinsic value of Agenus Inc. (AGEN)?

        Agenus Inc. (AGEN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AGEN undervalued?

        AGEN trades at a price of $5.97 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.